Results 141 to 150 of about 602,823 (332)

Safety and Efficacy Findings From a Phase Ib/II Study of ASP‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Head &Neck, EarlyView.
ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 ...
David M. Cognetti, Joseph M. Curry, Jennifer Johnson, Michael Kwon, Shirley Y. Su, Francisco Civantos, Coral Olazagasti, Joseph Valentino, Susanne M. Arnold, R. Bryan Bell, Michael K. Gibson, Kyle Mannion, Kathryn M. Van Abel, Katharine A. Price, Haiying Dong, Amy H. Thorne, Toshiaki Suzuki, Ann M. Gillenwater   +17 more
wiley   +1 more source

The effect of S-carboxymethylcysteine on ciliary beat frequency of nasal mucosa.

, 1988
Ryo Amesara, Kotaro Ukai, Akihiko Katoh, Satoshi Saida, Yasuo Sakakura   +4 more
openalex   +2 more sources

Histamine H₁‐receptors in the nasal mucosa: a mystery solved? [PDF]

, 1996
F. Estelle R. Simons, Paul C. Grimm
openalex   +1 more source

Patterns of Cervical Metastases and Implications for Neck Management in Minor Salivary Gland Cancer Treatment

Head &Neck, EarlyView.
ABSTRACT Objectives Minor salivary gland cancer (MiSGC) is a rare and heterogeneous disease, with different degrees of tumor aggressiveness. The scarce data in the literature show that the presence of lymph node metastases (LNMs) negatively impacts the prognosis.
Eduardo Wanderley Estanislau da Costa, Pedro Nicolau‐Neto, Paula Moretz‐Sohn, Bernardo Cacciari Peryassu, Emilson de Queiroz Freitas, Luis Felipe Ribeiro Pinto, Fernando Luiz Dias   +6 more
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, EarlyView.
What's New? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

The distribution of basophiloid cells in nasal mucosa.

, 1985
Kensuke Watanabe, YUSUO NIIZEKI, Makoto Hasegawa   +2 more
openalex   +2 more sources

Evaluation of Acute Exposure to Combustible and Novel Tobacco Products Using an In Vitro Human Airway Organ Tissue Equivalent Model

Journal of Applied Toxicology, EarlyView.
ABSTRACT Despite the well‐known risks of tobacco use, tobacco exposure remains a major contributor to morbidity and mortality worldwide. Although cigarette use has declined, the popularity of novel tobacco products (NTPs), such as electronic cigarettes (ECs) and heated tobacco products (HTPs), has increased.
Timothy S. Leach, Steven Albertson, Phillip W. Clapp, Vikram Surendran, Trang Simon, Eric C. Donny, Stephen J. Walker, Anthony Atala, Sean V. Murphy   +8 more
wiley   +1 more source

Author Correction: In vivo assessment of cerebrospinal fluid efflux to nasal mucosa in humans. [PDF]

Sci Rep, 2023
Melin E, Eide PK, Ringstad G.
europepmc   +1 more source

.BETA.-Adrenergic function on nasal mucosa of the patients with allergic rhinitis.

, 1986
Yuko Shiba, Tetsuzo Fujitani
openalex   +2 more sources

Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies

The Journal of Clinical Pharmacology, EarlyView.
Abstract Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being developed for the treatment of metabolic dysfunction‐associated steatohepatitis.
Hazel J. Hunt, Kirsteen M. Donaldson, Jeevan R. Kunta, Joseph M. Custodio   +3 more
wiley   +1 more source